Clinical Trials Logo

Relapsed Cancer clinical trials

View clinical trials related to Relapsed Cancer.

Filter by:

NCT ID: NCT04421560 Recruiting - Clinical trials for Primary Central Nervous System Lymphoma

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Start date: August 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: - Pembrolizumab (MK3475) - Ibrutinib - Rituximab (or biosimilar)

NCT ID: NCT04292119 Recruiting - Lung Cancer Clinical Trials

Lorlatinib Combinations in Lung Cancer

Start date: May 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is evaluating Lorlatinib in combination with Crizotinib, Binimetinib, or TNO155 as a possible treatment for either anaplastic lymphoma kinase (ALK)-positive lung cancer or ROS1-positive lung cancer. - This research study involves four study drugs. - Lorlatinib - Binimetinib - Crizotinib - TNO155